Systemic minimal residual disease after primary tumor treatment can remain asymptomatic for decades. This is thought to be due to the presence of dormant disseminated tumor cells (DTCs) or micrometastases in different organs. DTCs lodged in brain, lungs, livers and/or bone are a major clinical problem because they are the founders of metastasis, which ultimately kill cancer patients.
BACKGROUND
Origin and fate of disseminated tumor cells DTCs. The inherent complexity of metastasis biology has proven difficult to unravel (1) . Metastasis treatment with conventional chemotherapy is mostly ineffective because when diagnosed these lesions are already large (i.e. 10 10-10 11 tumor cells (2) ) and heterogeneous (3) . Moreover, the biological and genetic divergence between primary tumors and metastasis (4) further complicates treatment. Thus, a constant "catch-up" game is played with the robust genetic and epigenetic resourcefulness of metastases, where treatments are given sequentially until lesions become completely refractory.
Clinical tumor dormancy is the asymptomatic period between the time of primary tumor detection and treatment and its local or distant metastatic relapse. However, this time does not necessarily imply the presence of dormant disease and could be explained simply by tumor doubling times (1) . This argues for the need of better markers to define truly dormant residual disease. We distinguish tumor cell dormancy (i.e. of disseminated disease) from tumor latency that is mostly used to define the time from the carcinogenic event to the clinical diagnosis of the primary tumor (5) .
Dormancy of a micrometastatic mass where the proliferating population is balanced by a dying one may be due to failure to induce an angiogenic switch and/or to immune cell-mediated mechanisms (5) In contrast cellular tumor dormancy, which most likely explains solitary DTC dormancy can be explained by quiescence programs (a reversible growth arrest state) in which DTCs remain nonproductive until changes in microenvironment (i.e. lung, liver, bone marrow) signals activate them to resume growth (6) . These scenarios can unfold soon after primary tumor treatment (1-2 years) or decades later (6) .
By the time of diagnosis a large number of patients have already disseminated disease lodged in target organs in the form of solitary DTCs (1) . These DTCs can be found in secondary organs such as liver and sentinel lymph nodes (LN) as well as in bone marrow (BM) (7) . DTCs are commonly studied in bone marrow aspirates due to easy access to this compartment. However, the bone is not the only place where they reside. In fact, DTCs are most likely in multiple organs simultaneously and sampling of the BM provides a snapshot of what their behavior and characteristics might be systemically. It is widely accepted that these single DTCs are the seeds for later tumor metastases. It is proposed that circulating tumor cells (CTCs) (i.e. isolated from peripheral blood (8)) will become DTCs when lodged in a secondary tissues (e.g. lung, liver), but for the most part these are short-lived tumor cells in circulation that provide primarily a snapshot of recently intravasated tumor cells (9) and therefore of primary or secondary tumor masses that shed cells. But once the tumor is surgically removed CTC numbers commonly decrease, while DTCs can be detected for long periods (1) . Thus, these cells carry information on both their origin and how the target organ affects them. Unfortunately, because DTC biology is poorly understood, we currently miss the opportunity to eradicate these tumor cells and prevent metastasis (5) . Further, because non-proliferative DTCs (see below) may evade conventional therapies (5), a completely different approach might be needed to eradicate these cells.
Dormancy of DTCs might be explained by two complementary hypotheses. These propose that during cancer progression dissemination represents either early or late events. The first is supported by the frequent detection of BM DTCs in patients carrying non-invasive lesions (e.g., ADH or DCIS) (4). In MMTV-Neu (Neu) mice, where p38 antagonizes tumor development (10), premalignant lesions contained micro-invasive cells and dissemination to lungs and BM occurred early (11) . In uveal melanoma, a cancer with 50% incidence of late liver recurrence (>10 years) in humans (12) , analysis of tumor doubling times led to the conclusion that dissemination had occurred at least 5 years before diagnosis. In a mouse model of uveal melanoma (13) it was shown that dissemination occurred early and dormant DTCs (i.e. growth-arrested) were commonplace. In a D. melanogaster CSK null cancer model, early dissemination required Src activation without loss of E-cadherin or apparent EMT induction (14) . Early DTCs might carry robust survival signals but still lack key genetic and epigenetic changes to sustain proliferation (11) . In consequence, prolonged growth arrest with interspersed division might explain the clinical dormancy during which slow accumulation of genetic and/or epigenetic alterations give rise to malignant DTCs and relapse. For an excellent recent review see the article by Klein (1) . Finally, late DTCs that progressed in the primary tumor may reprogram into quiescence and co-exist with early DTCs in patients with invasive cancers (5) that can display long metastases-free periods. This might be regulated by metastasis suppressor genes (MSG) that can respond to microenvironmental stress responses (15) . There is a growing number of these genes that selectively affect growth at secondary sites and they include KISS1, MKK4, MKK6, BHLHLB3/Sharp-1 and Nm23-H1 among others (15) . For a comprehensive review see (15) . These genes may inhibit metastasis by inducing DTC growth arrest, preventing the formation of overt metastases (15) . Interestingly, MKK4 and MKK6 are upstream activators of p38 (15) (18) . Three subfamilies exist in mammals and include ERK, JNK and p38 kinases. Four isoforms (α, β, γ and δ) constitute the p38 family. They were initially identified as modulators of inflammatory responses where they regulate the expression of different cytokines (18) . Furthermore, they were also found to play important roles in cell proliferation by activating G1/S and G2/M checkpoints (18) . It is also known that p38 can suppress transformation of normal epithelial cells (19) (20) (21) and it activates anoikis, which prevents aberrant localization of epithelial cells (19) . In addition, p38α can promote growth arrest by downregulating cyclin D1 (21) and by activating the p53 to p21 and/or p16 to Rb pathways (22, 23) among others (24) . Further, p38α inhibits transformation by sensing oncogene-induced oxidative stress (25) , inactivation of p38α facilitates ErbB2-induced mammary tumorigenesis in vivo (10, 22) and ~18% of human primary breast carcinomas display Wip1/PPM1D (a p38 phosphatase) amplification (10, 22) . Thus, Wip1 inhibitors (26) might be useful to restore p38α signaling in tumors.
Activation of p38α can also cooperate with reduced ERK1/2 mitogenic signaling to induce quiescence of tumor cells (Fig1) (16) . Furthermore, as mentioned above metastasis suppressor genes (i.e. MKK4) can act upstream or downstream of p38 activation (27) . Despite these advances, how p38α signaling is spatio-temporally regulated during cancer progression to suppress early tumorigenesis, dissemination or to prevent DTCs from becoming overt metastasis is still unclear.
P38α/β REGULATES EARLY BREAST CANCER PROGRESSION AND DISSEMINATION.
Activation of p38α/β is a barrier to mammary tumor progression (10) . We recently pinpointed this function of p38α during mammary morphogenesis by demonstrating that it activates anoikis of centrally located luminal ductal cells during mammary acinar development (28) . This work revealed that p38α inhibited ERK1/2 possibly by regulation of PP2A and MKP phosphatases (29) and activated ATF-2 to induce c-Jun.
Then, jointly, these TFs along with reduced ERK1/2 activity induced the pro-apoptotic factor BimEL in cells devoid of integrin-mediated attachment (28) . This triggered anoikis and lumen formation.
Remarkably, this leads to the formation of structures reminiscent of DCIS (28) . In MMTV-Neu mice, where dissemination occurs during pre-malignant stages (11), p38α/β inhibition accelerated premalignant lesion development, lumen occupancy and local migration of both the epithelial and myoepithelial cells (28) . Histological analysis of normal FVB or MMTV-Neu mammary glands showed enhanced ERK1/2 phosphorylation and reduction of E-cadherin levels in luminal epithelial cells (unpublished data) when p38 was inhibited. This was sufficient to enhance dissemination as p38α/β inhibition more than doubled the number of disseminated tumor cells (Her2+, CK8/18+ (11)) in the BM (unpublished data). These data suggest that p38 signaling might simultaneously prevent early cancer progression (18, 28) and early dissemination almost simultaneously. We further propose that early DTCs might retain functional p38 signaling and perhaps metastasis suppressor gene expression which restricts colonization of distant organs by contributing to clearance (via anoikis? (19) 
Dormancy of a tumor mass vs. dormancy of tumor cells. The lack of proliferation markers in surviving
DTCs in patients and data from experimental systems suggest that DTC dormancy might be controlled by mechanisms of quiescence (5), a reversible growth arrest that can be brought about by different signals (30) . Further, specific transcription factors (TFs) can prevent quiescent cells from entering differentiation or senescence (an irreversible growth arrest that can lead to cell death or clearing by phagocytic cells) (30) , two cellular end points that tumor cells can evade (31) . Angiogenic dormancy or immune system-mediated tumor mass dormancy might also be of importance in certain contexts (32, 33) . Interestingly, anti-angiogenesis and quiescence programs might be coupled, as there are many common regulated genes in angiogenic dormancy (32) and quiescence models (16) .
Recent studies also suggest that immune cell-mediated dormancy might require the induction of tumor cell growth arrest as well (13, 34) .
ECM and stress signaling regulation of dormancy. The seed and soil theory would support the idea that the interactions DTCs establish with target organ ECM, or stromal cells (35) could determine growth vs. dormancy and dictate the distinct and predictable pattern of metastasis (5) . Studies on breast cancer cell lines selected for growth in the bone for example show that these cells selectively regulate gene expression programs that favor organ specific colonization (36) . In squamous carcinoma cells (HEp3) it was shown that reduced urokinase receptor expression α5β1-integrins made these cells incapable of binding efficiently to fibronectin (Fig1) (37) . This resulted in reduced FAK and EGFR signaling but also in p38 activation. Other groups have corroborated these findings showing that loss of β1-integrin or FAK signaling in the mammary epithelium or in intravenously delivered mouse breast cancer cells can also induce dormancy and that Src MLKC signaling can prevent dormancy onset (5, 38) . It was also shown that activation of p38 by blockade of adhesion signaling resulted in further inhibition of ERK1/2 while also activating a stress adaptive response known as the unfolded protein response (UPR) (16, 39 acquisition of a dormant phenotype by HEp3 (D-HEp3) cells (40) that was characterized by a deep G 0 -G 1 arrest associated with p21, p27, p18 and p15 induction and only observed in vivo ( (16) and unpublished results) (Fig1). Activation of p38α/β induced at least 3 TFs, p53 (R213Qmut), BHLHB3/41/Sharp1, NR2F1 and inhibited the expression of c-Jun and FOXM1, two G1-S transition TFs (16) . Importantly, the R213Q mutation in p53 does not affect its ability to induce G0/G1 arrest but it prevents the induction of senescence or apoptosis ( (16) differentiation programs while promoting quiescence (30) . This suggests that growth-arrested tumor cells might activate quiescence-specific survival mechanisms that render them resistant to microenvironmental and genotoxic stress. Inhibition of these alternative survival pathways could be exploited to induce cell death in quiescent DTCs.
CLINICAL -TRANSLATIONAL ADVANCES.
Our knowledge on how the biology and genetics of DTCs influence dormancy and progression is limited. In consequence there are no available dormancy inducing or dormant cell killing drugs. Nevertheless, several translational or clinical applications can be envisioned. One is the necessary characterization of the dormant DTCs to identify the mechanisms driving dormancy. The other is determining whether current therapies can be applied to maintain dormancy of residual disease. In the first case major basic-translational research effort must go into "information-gathering" by characterizing DTCs during asymptomatic periods both in the laboratory and in patients (56, 57) . Further, better pre-clinical models must be developed to reproduce the kinetics of disseminated residual disease in patients. Harnessing single-cell profiling technologies (7, 58) to study DTCs in an unbiased manner will also shed light into the genetics and epigenetics of DTC behavior and whether available targeted therapies could be applied, or not, to dormant tumor cells. An excellent review by Chambers and Goss highlights this latter possibility (59) .
For example, in ER+/PR+ breast cancer recurrences continue to develop after the initial 5 years of conventional anti-estrogen treatment. Among different clinical trials that are described for different cancer types, several clinical trials showed that following a 5-year treatment with tamoxifen for these breast tumors, treatment with the aromatase inhibitor (Letrizole) has additional benefit by further delaying recurrence with treatment schedules spanning >5 years (59) . Interestingly, tamoxifen treatment can activate p38 signaling and quiescence (60) , suggesting that these "dormancy" therapies might tap into some of the mechanisms described here. This strategy could be considered a maintenance therapy that prevents DTCs from exiting a state of growth arrest (i.e. dormancy maintenance) or by inducing growth arrest (i.e. dormancy induction). However, such a strategy might select for ER-negative tumor cells (59) . This may be due to the fact that in order to induce a program of quiescence simply inhibiting mitogenic signaling (i.e. RTK, Raf or Mek1/2 inhibitors) will not be sufficient. Perhaps, in addition, activation of stress signals like p38 or downstream TFs (or others) might be crucial to achieve a long-term stable dormant phenotype (16) . In cutaneous but most prominently uveal melanoma late recurrences have been described (12) . Although the association between genetics and time to recurrence is not abundant a small study showed that that longer disease-free survival periods were associated with B-Raf but not N-Ras mutations (12) . Thus, it is possible that in certain patients, B-Raf+ residual melanoma cells might be kept "dormant" by treating 
herceptin) used to treat other cancers might be useful in maintaining residual disease by treating patients during asymptomatic periods. This approach might keep cells from interrupting dormancy but will not eliminate the quiescent DTCs. Thus, ultimately specific targeting of dormant tumor cells might come only from a full molecular description of these cells. An important example of how analysis of DTCs might provide information different from that obtained from primary tumors came from studying DTCs in esophageal cancer (7) . This work revealed that DTCs displayed frequent Her2/neu amplification and this significantly correlated with poor prognosis (7). This information could not be derived from primary tumor analysis and opens the possibility of treating disseminated disease in this type of cancer with therapies already available (i.e. herceptin, lapatinib) originally for breast cancer.
The most successful clinical trial would be that testing a drug targets dormant tumor cells while quiescent (5) . Unfortunately specific drugs to achieve this goal are currently unavailable and they might be identified only after we understand how therapy and micro-environmental cues influence DTC quiescence and survival. The prevalence of p38 signaling as a negative regulator of cancer progression and as an inducer of dormancy has additional significance. Inhibitors of p38 (such as SCIO-469, RO4402257, PH-797804, SB681323 and BMS-582949) are currently in clinical trials for several neoplastic and non-neoplastic diseases (e.g., hematological malignancies, asthma, neuropathic pain, atherosclerosis, rheumatoid arthritis, etc; www.clinicaltrials.gov and Table 1 ). Thus, understanding how p38 inhibitors might carry an inherent risk for a proportion of patients with cancer, with predisposition to cancer, or with other diseases is of crucial importance as inhibition of this pathway may fuel cancer progression and metastasis in these patients.
It will be important to determine whether the genes that define growth vs. dormancy in the different experimental models (16, 32, 38, 41, 42) markers? The findings that lung fibrosis (38) interrupts dormancy of DTCs, suggests also that monitoring the composition of the target organ in specific cancers may predict relapse in certain patients. Thus, a short term translational or clinical benefit from studying DTCs will be the identification of markers to classify patients with dormant (protractedly non-productive (1)) or active (productive) disseminated disease. These markers would be target organ microenvironment-(i.e. collagen-I fibrotic tissues (38) ) and DTC-derived. Moreover, the combinatorial use of drugs that modify stromal cells in the target organ microenvironment, for example macrophages that might support metastatic growth (35) , may add further advantages to the treatment. The challenges are big and studying DTCs and dormant disease is a difficult task, but the benefits of these efforts should be of great impact for cancer patients.
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We would like to thank the members of our lab for helpful discussions. scenario prevails and tumor cells are able to disseminate carrying this cell signaling profile. One scenario proposes that as these cells reach a growth-permissive target tissue microenvironment (e.g. lung) a proliferative phenotype prevails and dormancy is prevented. In contrast, in growth-restrictive sites such as the bone marrow a dormant phenotype prevails (G0/G1 arrest + basal survival + adaptive survival). This latter scenario presupposes that DTCs are responsive to cues from the tissue microenvironment that can modulate dormancy. It is possible that perturbations of the tissue microenvironment (i.e. irradiation) or the presence of specific stromal cells such as macrophages (not depicted) that lead to tissue remodeling and crosstalk with tumor cells might interrupt dormancy leading to metastasis. 
